Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients.
Biomarkers
COVID-19
/ diagnosis
COVID-19 Serological Testing
Cytokines
/ blood
Disease Progression
Hospitalization
Humans
Immunophenotyping
Inflammation Mediators
/ blood
Lymphocyte Count
Prognosis
Public Health Surveillance
ROC Curve
SARS-CoV-2
/ immunology
Severity of Illness Index
T-Lymphocyte Subsets
/ immunology
T-Lymphocytes, Regulatory
/ immunology
COVID-19
T cell subtypes
disease severity
immunophenotype
regulatory T cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
10
2021
accepted:
15
11
2021
entrez:
20
12
2021
pubmed:
21
12
2021
medline:
5
1
2022
Statut:
epublish
Résumé
The host immune response has a prominent role in the progression and outcome of SARS-CoV-2 infection. Lymphopenia has been described as an important feature of SARS-CoV-2 infection and has been associated with severe disease manifestation. Lymphocyte dysregulation and hyper-inflammation have been shown to be associated with a more severe clinical course; however, a T cell subpopulation whose dysfunction correlate with disease progression has yet to be identify. We performed an immuno-phenotypic analysis of T cell sub-populations in peripheral blood from patients affected by different severity of COVID-19 (n=60) and undergoing a different clinical evolution. Clinical severity was established based on a modified WHO score considering both ventilation support and respiratory capacity (PaO2/FiO2 ratio). The ability of circulating cells at baseline to predict the probability of clinical aggravation was explored through multivariate regression analyses. The immuno-phenotypic analysis performed by multi-colour flow cytometry confirmed that patients suffering from severe COVID-19 harboured significantly reduced circulating T cell subsets, especially for CD4 The present study demonstrates the association between CD4
Sections du résumé
Background
The host immune response has a prominent role in the progression and outcome of SARS-CoV-2 infection. Lymphopenia has been described as an important feature of SARS-CoV-2 infection and has been associated with severe disease manifestation. Lymphocyte dysregulation and hyper-inflammation have been shown to be associated with a more severe clinical course; however, a T cell subpopulation whose dysfunction correlate with disease progression has yet to be identify.
Methods
We performed an immuno-phenotypic analysis of T cell sub-populations in peripheral blood from patients affected by different severity of COVID-19 (n=60) and undergoing a different clinical evolution. Clinical severity was established based on a modified WHO score considering both ventilation support and respiratory capacity (PaO2/FiO2 ratio). The ability of circulating cells at baseline to predict the probability of clinical aggravation was explored through multivariate regression analyses.
Results
The immuno-phenotypic analysis performed by multi-colour flow cytometry confirmed that patients suffering from severe COVID-19 harboured significantly reduced circulating T cell subsets, especially for CD4
Conclusions
The present study demonstrates the association between CD4
Identifiants
pubmed: 34925369
doi: 10.3389/fimmu.2021.789735
pmc: PMC8674838
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Inflammation Mediators
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
789735Informations de copyright
Copyright © 2021 Caldrer, Mazzi, Bernardi, Prato, Ronzoni, Rodari, Angheben, Piubelli and Tiberti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Ann Hematol. 2020 Jun;99(6):1419-1420
pubmed: 32382776
Front Immunol. 2020 Oct 08;11:589380
pubmed: 33178221
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
J Infect Dis. 2020 Jun 29;222(2):198-202
pubmed: 32379887
Leukemia. 2012 Sep;26(9):1986-2010
pubmed: 22948490
J Infect. 2020 Aug;81(2):318-356
pubmed: 32283159
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
Immunology. 2021 Jan;162(1):30-43
pubmed: 32935333
J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4
pubmed: 32360286
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Clin Chim Acta. 2020 Sep;508:110-114
pubmed: 32405080
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Cytometry A. 2020 Aug;97(8):772-776
pubmed: 32542842
Nat Commun. 2021 Jun 30;12(1):4043
pubmed: 34193870
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Nat Commun. 2020 Jul 8;11(1):3410
pubmed: 32641700
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
Front Immunol. 2020 Jun 16;11:1441
pubmed: 32612615
J Clin Invest. 2020 Dec 1;130(12):6477-6489
pubmed: 32833687
Genomics. 2021 Jul;113(4):1628-1638
pubmed: 33839270
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32353870
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Cytokine. 2021 Jan;137:155323
pubmed: 33045526
Front Immunol. 2021 Mar 11;12:655934
pubmed: 33777054
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059